# **Special Issue**

# Hepatitis B Virus and Liver Cancer: Molecular Mechanisms and Approaches for the Prevention

## Message from the Guest Editor

Hepatitis B virus (HBV) infection is one of worldwide health problems because patients who were chronically infected with HBV are at risk of liver cirrhosis and liver cancer including hepatocellular carcinoma (HCC). Such patients are treated with nucleoside/nucleotide analogues or interferon, but the risk of liver cancer still remains during/after therapies. There seem to be several mechanisms of hepatocarcinogenesis due to HBV chronic infection, but it is not fully understood. In this special issue, we would like to accept manuscrips regarding the mechanisms for the development of HBV-associated liver cancer and its potential applications for therapies. Also, we would like to discuss the advantages and disadvantages of current and future therapies for the prevention of liver cancer.

### **Guest Editor**

Dr. Jun Inoue

Division of Gastroenterology, Tohoku University Graduate School of Medicine, Tokyo, Japan

### Deadline for manuscript submissions

closed (31 December 2021)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/71777

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

